BioCryst Pharmaceuticals Inc. [BCRX] stock Upgrade by Evercore ISI analyst, price target now $16

BioCryst Pharmaceuticals Inc. [NASDAQ: BCRX] price surged by 3.41 percent to reach at $0.39. The company report on January 4, 2023 that BioCryst to Present at 41st Annual J.P. Morgan Healthcare Conference.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…


Links to the live audio webcast and replay of the presentation may be accessed in the Investors & Media section of BioCryst’s website at

A sum of 4032955 shares traded at recent session while its average daily volume was at 2.74M shares. BioCryst Pharmaceuticals Inc. shares reached a high of $11.985 and dropped to a low of $11.40 until finishing in the latest session at $11.84.

The one-year BCRX stock forecast points to a potential upside of 29.52. The average equity rating for BCRX stock is currently 2.50, trading closer to a bullish pattern in the stock market.

Guru’s Opinion on BioCryst Pharmaceuticals Inc. [BCRX]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for BCRX shares is $16.80 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on BCRX stock is a recommendation set at 2.50. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Evercore ISI have made an estimate for BioCryst Pharmaceuticals Inc. shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on November 02, 2022. The new note on the price target was released on August 05, 2022, representing the official price target for BioCryst Pharmaceuticals Inc. stock. Previously, the target price had yet another raise to $14, while Evercore ISI analysts kept a In-line rating on BCRX stock. On April 18, 2022, analysts decreased their price target for BCRX shares from 22 to 13.

The Average True Range (ATR) for BioCryst Pharmaceuticals Inc. is set at 0.56, with the Price to Sales ratio for BCRX stock in the period of the last 12 months amounting to 9.01.

BCRX Stock Performance Analysis:

BioCryst Pharmaceuticals Inc. [BCRX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 8.42. With this latest performance, BCRX shares dropped by -7.43% in over the last four-week period, additionally plugging by 5.43% over the last 6 months – not to mention a drop of -15.85% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for BCRX stock in for the last two-week period is set at 54.78, with the RSI for the last a single of trading hit 62.10, and the three-weeks RSI is set at 51.17 for BioCryst Pharmaceuticals Inc. [BCRX]. The present Moving Average for the last 50 days of trading for this stock 12.05, while it was recorded at 11.35 for the last single week of trading, and 12.10 for the last 200 days.

Insight into BioCryst Pharmaceuticals Inc. Fundamentals:

Operating Margin for any stock indicates how profitable investing would be, and BioCryst Pharmaceuticals Inc. [BCRX] shares currently have an operating margin of -113.08 and a Gross Margin at +94.88. BioCryst Pharmaceuticals Inc.’s Net Margin is presently recorded at -117.11.

BioCryst Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 5.90 and a Current Ratio set at 6.20.


The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for BCRX. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for BioCryst Pharmaceuticals Inc. go to 15.20%.

BioCryst Pharmaceuticals Inc. [BCRX] Insider Position Details

There are presently around $1,748 million, or 81.10% of BCRX stock, in the hands of institutional investors. The top three institutional holders of BCRX stocks are: VANGUARD GROUP INC with ownership of 13,838,612, which is approximately 0.206% of the company’s market cap and around 0.80% of the total institutional ownership; BLACKROCK INC., holding 13,774,995 shares of the stock with an approximate value of $163.1 million in BCRX stocks shares; and BAKER BROS. ADVISORS LP, currently with $150.5 million in BCRX stock with ownership of nearly 0% of the company’s market capitalization.

Positions in BioCryst Pharmaceuticals Inc. stocks held by institutional investors increased at the end of February and at the time of the February reporting period, where 121 institutional holders increased their position in BioCryst Pharmaceuticals Inc. [NASDAQ:BCRX] by around 12,785,259 shares. Additionally, 85 investors decreased positions by around 15,093,388 shares, while 56 investors held positions by with 119,757,445 shares. The mentioned changes placed institutional holdings at 147,636,092 shares, according to the latest SEC report filing. BCRX stock had 41 new institutional investments in for a total of 4,067,268 shares, while 27 institutional investors sold positions of 2,754,111 shares during the same period.


Please enter your comment!
Please enter your name here